Japans big bet on stem-cell therapies might soon pay off with medical breakthroughs  Nature

The rest is here:
Japans big bet on stem-cell therapies might soon pay off with medical breakthroughs - Nature

The Future of Medicine: Japan Forges Ahead in iPS Cell Research  nippon.com

Excerpt from:
The Future of Medicine: Japan Forges Ahead in iPS Cell Research - nippon.com

Pioneering a Cure for Parkinson's Disease: First Allogeneic iPS Cell-Based Therapy Demonstrates Safety and Efficacy  cira.kyoto-u.ac.jp

More:
Pioneering a Cure for Parkinson's Disease: First Allogeneic iPS Cell-Based Therapy Demonstrates Safety and Efficacy - cira.kyoto-u.ac.jp

Dont rush promising stem-cell therapies  Nature

See the article here:
Dont rush promising stem-cell therapies - Nature

Clinical trials test the safety of stem-cell therapy for Parkinsons disease  Nature

Read more:
Clinical trials test the safety of stem-cell therapy for Parkinsons disease - Nature

Kyoto University Team Achieves Breakthrough In Parkinson's Treatment  Evrim Aac

Read the original:
Kyoto University Team Achieves Breakthrough In Parkinson's Treatment - Evrim Aac

Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)  Nature

View original post here:
Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem...

What are stem cells and why are they a lifesaving cure for blood cancer?  India Today

Excerpt from:
What are stem cells and why are they a lifesaving cure for blood cancer? - India Today

Stem Cell Therapies Could Treat Parkinson's Disease by Rebuilding Lost Circuitry in the Brain, Studies Suggest  Smithsonian Magazine

Read the rest here:
Stem Cell Therapies Could Treat Parkinson's Disease by Rebuilding Lost Circuitry in the Brain, Studies Suggest - Smithsonian Magazine

Autologous Versus Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy for Knee Osteoarthritis: A Systematic Review, Pairwise and Network Meta-Analysis of Randomized Controlled Trials  Cureus

Original post:
Autologous Versus Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy for Knee Osteoarthritis: A Systematic Review, Pairwise and Network...

Exploring the mechanism of bone marrow mesenchymal stromal cell exosomes in respiratory syncytial virus infection based on miRNA sequencing  Nature

Read more here:
Exploring the mechanism of bone marrow mesenchymal stromal cell exosomes in respiratory syncytial virus infection based on miRNA sequencing - Nature

hBMEC altered CD34 expression in HSPC. HSPC were irradiated (2, 4 Gy...  ResearchGate

Read more here:
hBMEC altered CD34 expression in HSPC. HSPC were irradiated (2, 4 Gy... - ResearchGate

April 11, 2025

Link:
Preliminary Results for the Year Ended 31 December 2024

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.

Visit link:
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-35, to be effective as of 12:01 a.m. Eastern Time on April 15, 2025.

Continued here:
Scilex Holding Company Announces 1-for-35 Reverse Stock Split

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress

See original here:
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases

See the original post:
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

HENDERSON, Nev., April 11, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) published a report on the therapeutic effect and potential economic impact of ITV-1. The document contains the company’s findings on the effects of the drug on volunteers suffering from AIDS, cancer and other diseases. It details several examples of the curative effect of ITV-1 and its wider applicability beyond AIDS. You can read the document here or on our website.

Read the rest here:
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments

GLASGOW, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- There are relatively few testosterone boosters with natural substances that have been clinically shown to increase testosterone levels without producing side effects.

The rest is here:
TestoPrime Reviews: Best Testosterone Booster Supplement For Men Over 40 & 50 – Is TestoPrime Tablets Safe?

Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate

Continued here:
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and...